|Bid||76.01 x 800|
|Ask||76.06 x 3000|
|Day's Range||75.56 - 76.38|
|52 Week Range||69.10 - 95.19|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||43.03|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||0.98 (1.27%)|
|Ex-Dividend Date||Dec 03, 2020|
|1y Target Est||94.35|
Baxter announced a $50 million expansion of its sterile fill/finish manufacturing facilities located in Bloomington, Ind.
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform. Homechoice Claria combines a simple user interface with the benefits of Sharesource, the only two-way remote patient management platform for patients on peritoneal dialysis in the U.S. Homechoice Claria is cleared for both adult and pediatric populations.1 The clearance follows the recent finalization of the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, which aims to significantly increase the number of new patients with kidney failure who receive home dialysis and/or organ transplants.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 3rd Annual HealthCONx virtual conference via webcast on Tuesday, December 1, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:20 a.m. Eastern Time.